Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection – GlobeNewswire (press release)
|
Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection
GlobeNewswire (press release) PLYMOUTH MEETING, Pa., March 14, 2018 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis B virus (HBV) infection was safe, well-tolerated and … Inovio Pharma (INO) Announces Interim Phase 1 Results for DNA Immunotherapy to Treat HBV |
